Organigram Global Inc.
NASDAQ:OGIDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $95.40M
- Beta
- 1.84
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$0.19
Volume 0.62M
Average 0.67M
OGI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Organigram Global Inc.NASDAQ: OGI
Research & Development · Q2 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of CA$2.03M fell 23.9% year over year, behind the +9.4% change in trailing-twelve-month research & development. Sequentially, it fell 2.8% from the prior quarter.
Context
- Research & development amounted to 5.9% of revenue in FY2025, down 1.1 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -23.9% toward the trailing-twelve-month pace of +9.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 10.95M CAD
- Year-over-year change
- -2.3%
- 4-year CAGR
- +33.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 10.95M | -2.3% |
| FY2024 | 2024-09-30 | 11.2M | -8.1% |
| FY2023 | 2023-09-30 | 12.19M | +104.4% |
| FY2022 | 2022-08-31 | 5.96M | +72.8% |
| FY2021 | 2021-08-31 | 3.45M | — |
Research & Development vs competitors
How OGI compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.4% is the 5th highest of 8, against a peer median of +25.5%.
- Research & development amounts to 3.7% of revenue for OGI, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €83.61M EUR | -8.0% | +11.4% | 1865.0% | |
| LTM Mar 2026 | $62.82M USD | +25.5% | -7.1% | 3539.3% | |
| LTM Mar 2026 | $60.48M USD | +28.2% | +38.4% | 184.8% | |
| LTM Mar 2026 | CA$10.02M CAD | +9.4% | — | 3.7% | |
| LTM Mar 2026 | $7.58M USD | — | +1.8% | 5.6% | |
| LTM Mar 2026 | CA$4.98M CAD | +35.4% | +1.4% | 1.6% | |
| LTM Mar 2026 | $2.57M USD | -32.8% | -6.3% | 26.8% | |
| LTM Mar 2026 | $1.29M USD | +48.0% | -9.8% | 1.8% | |
| LTM Mar 2026 | $441K USD | -78.1% | -64.7% | 0.7% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding OGI) | — | +25.5% | -2.4% | 5.6% | |
Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Aug 2021 | FY2022 Aug 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 79.16M | 145.81M | 149.21M | 159.84M | 186.09M |
| Cost of Revenue | 107.56M | 114.24M | 114.13M | 112.32M | 179.26M |
| Gross Profit | (28.4M) | 31.57M | 35.07M | 47.52M | 6.83M |
| Gross Margin | -35.9% | 21.7% | 23.5% | 29.7% | 3.7% |
| Research & Development | 3.45M | 5.96M | 12.19M | 11.2M | 10.95M |
| Selling, General & Admin | 46.47M | 59.21M | 71.68M | 68.14M | 86.88M |
| Operating Expenses | 63.42M | 74.72M | 271.48M | 83.2M | 70.24M |
| Depreciation & Amortization | 31.03M | 24.91M | 23.43M | 12.08M | 12.91M |
| EBITDA | (96.71M) | 10.97M | (25.37M) | (23.59M) | (14.76M) |
| EBITDA Margin | -122.2% | 7.5% | -17.0% | -14.8% | -7.9% |
| Operating Income | (91.82M) | (43.15M) | (242.74M) | (35.67M) | (63.41M) |
| Operating Margin | -116.0% | -29.6% | -162.7% | -22.3% | -34.1% |
| Interest Income | 0 | 0 | 3.69M | 0 | 825.7K |
| Interest Expense | 2.96M | 429K | 277.85K | 0 | 0 |
| Other Income / Expenses | (38.88M) | 28.78M | (184.21M) | (9.77M) | 35.74M |
| Income Before Tax | (130.7M) | (14.37M) | (233M) | (45.44M) | (27.66M) |
| Pre-Tax Margin | -165.1% | -9.9% | -156.2% | -28.4% | -14.9% |
| Income Tax Expense | 0 | (88K) | (3.52M) | 0 | (9.89M) |
| Net Income | (130.7M) | (14.28M) | (229.48M) | (45.44M) | (17.78M) |
| Net Margin | -165.1% | -9.8% | -153.8% | -28.4% | -9.6% |
| EPS (Basic) | (2.04) | (0.18) | (2.82) | (0.48) | (0.14) |
| EPS (Diluted) | (2.04) | (0.18) | (2.82) | (0.48) | (0.14) |
| Weighted Avg Shares | 64.03M | 80.01M | 81.29M | 95.29M | 127.67M |
| Weighted Avg Shares (Diluted) | 64.03M | 85.3M | 81.29M | 95.29M | 127.67M |
Organigram Global Inc.
NASDAQ:OGI
Intrinsic Alpha fair value
Locked
Current Price
$0.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.